It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Respiratory syncytial virus (RSV) is a leading cause of Acute Respiratory Tract Infections (ARTIs) in young children. However, there is currently no vaccine or treatment available for children. Here, we demonstrated that nasal-spraying probiotics containing 5 billion of Bacillus spores (LiveSpo Navax) is an effective symptomatic treatment in a 6-day randomized controlled clinical study for RSV-infected children (n = 40–46/group). Navax treatment resulted in 1-day faster recovery-time and 10–50% better efficacy in relieving ARTI symptoms. At day 3, RSV load and level of pro-inflammatory cytokines in nasopharyngeal samples was reduced by 630 folds and 2.7–12.7 folds respectively. This showed 53-fold and 1.8–3.6-fold more effective than those in the control-standard of care-group. In summary, nasal-spraying Bacillus spores can rapidly and effectively relieve symptoms of RSV-induced ARTIs while exhibit strong impacts in reducing viral load and inflammation. Our nasal-spraying probiotics may provide a basis for simple-to-use, low-cost, and effective treatment against viral infection in general.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 National Children’s Hospital, Department of Surgical Intensive Care Unit, Hanoi, Vietnam
2 National Children’s Hospital, International Center, Hanoi, Vietnam
3 National Children’s Hospital, Department of Molecular Biology for Infectious Diseases, Hanoi, Vietnam
4 VNU University of Science, Vietnam National University, Hanoi, Key Laboratory of Enzyme and Protein Technology, Hanoi, Vietnam (GRID:grid.493130.c); ANABIO R&D Ltd. Company, Spobiotic Research Center, Hanoi, Vietnam (GRID:grid.493130.c)
5 National Children’s Hospital, International Center, Hanoi, Vietnam (GRID:grid.493130.c)
6 ANABIO R&D Ltd. Company, Spobiotic Research Center, Hanoi, Vietnam (GRID:grid.493130.c); LiveSpo Pharma Ltd. Company, Hanoi, Vietnam (GRID:grid.493130.c)
7 VNU University of Science, Vietnam National University, Hanoi, Key Laboratory of Enzyme and Protein Technology, Hanoi, Vietnam (GRID:grid.493130.c)